{"id":"oraverse-injectable-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OraVerse works as a non-selective alpha-adrenergic antagonist that competitively blocks the effects of epinephrine and norepinephrine used in local anesthetic formulations. By antagonizing alpha-1 and alpha-2 adrenergic receptors in the vasculature, it promotes vasodilation and accelerates the resorption and clearance of the vasoconstrictor, thereby reducing the duration of local anesthesia-induced numbness and hemostasis.","oneSentence":"OraVerse is a phentolamine mesylate injectable that reverses the effects of local anesthetic vasoconstrictors by blocking alpha-adrenergic receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:54.824Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures"}]},"trialDetails":[{"nctId":"NCT05448807","phase":"PHASE3","title":"Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Children","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-07-05","conditions":"Soft Tissue Injuries","enrollment":100},{"nctId":"NCT05473858","phase":"PHASE3","title":"Oraverse Versus Laser","status":"UNKNOWN","sponsor":"sara nabil","startDate":"2021-12-10","conditions":"Reversal of Local Anesthesia in Children","enrollment":40},{"nctId":"NCT01474382","phase":"PHASE4","title":"Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients","status":"COMPLETED","sponsor":"Novocol Pharmaceutical of Canada, Inc.","startDate":"2012-02","conditions":"Dental Anesthesia, Anesthesia, Local, Anesthesia, Reversal","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OraVerse Injectable Product","genericName":"OraVerse Injectable Product","companyName":"sara nabil","companyId":"sara-nabil","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OraVerse is a phentolamine mesylate injectable that reverses the effects of local anesthetic vasoconstrictors by blocking alpha-adrenergic receptors. Used for Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}